Kevin Kelly
University of Southern California · Thomas Jefferson University · Yale New Haven Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin Kelly as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:24 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03330821 · Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaUniversity of Southern California · active not recruiting · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT02555189 · Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma ExpressionSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · terminated · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone · principal investigator
- Ph1NCT02514382 · Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaUniversity of Southern California · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph2NCT00557037 · A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate CancerMEI Pharma, Inc. · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Research Training and Education CoordinationP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Josh Neman-Ebrahim · fiscal years 2000 to 2026Named on NCT03330821, NCT02514382
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:24 UTC. The ranking covers the 200 most relevant of 357 PubMed records, and a shared surname and initials can bring in a namesake. All 357 on PubMed
- Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula.Gastroenterology · 1995813 citationsRCR 25.5
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.J Clin Oncol · 2017486 citationsRCR 15.1
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.JAMA Oncol · 2019397 citationsRCR 13.6
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Clin Cancer Res · 2016316 citationsRCR 9.3
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Leukemia · 2015283 citationsRCR 8.0
- Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.Lancet Oncol · 2017275 citationsRCR 10.0
- 248 citationsRCR 13.0
- 240 citationsRCR 6.4
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- 207 citationsRCR 11.3